Taking the Pain Out of Blood Collection

YourBio Heath is a medical device company dedicated to improving the blood draw experience. YouBio Health designed and developed Touch Activated Phlebotomy (TAP®), the world’s first push-button blood collection technology that enables TAP® Micro and TAP® Micro Select devices to make the blood sampling process simple, convenient, and virtually painless.

Exciting Instruments is revolutionising single-molecule spectroscopy with a compact, user-friendly EI-FLEX device, designed for high-throughput drug discovery and accessible operation outside traditional lab constraints. An affordable bench-top instrument capable of two-colour, single-molecule fluorescence detection in solution. The EI-FLEX is a versatile tool for studying protein conformations and bimolecular interactions. Now smFRET and FCS experiments are accessible at a benchtop without optical tables or dark rooms.

EnPlusOne is enabling the future of RNA and RNA solutions. Its ezRNA™ synthesis platform is a revolutionary innovation that can incorporate a diverse array of nucleotide modifications. The promise of sustainably delivering therapeutic RNA at commercial scale has arrived. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications

Relation discovers new biology to cure disease faster, transforming the traditional R&D model: because patients are waiting. Integral to this, Relation combines the power of active-graph machine learning and large-scale, high-quality data that describes disease biology to find better ways of targeting human pathology. We generate proprietary maps of disease in humans, leveraging human genetics, single-cell omics and perturbational data, so that these powerful models can be deployed at last. Relation’s platform sits in an integrated wet-lab, dry-lab, translational science loop, located in London.

Harbinger Health is pioneering thttps://www.camilluslife.com/he detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. 

Oxford Immune Algorithmics is a deep-tech start-up that aims to apply super-human-like Artificial General Intelligence (AGI) to tackle disease and bring decentralised, precise and personalised medicine to everyone. Algocyte is Oxford Immune Algorithmics’s flagship product, a cutting-edge AI-driven solution to monitor people’s health that includes minimally invasive intelligent blood testing and lifestyle data collection. Algocyte combines mechatronics, optics, chemistry, and cell biology with responsible computational intelligence to mimic and enhance human medical reasoning and decision-making in order to create each individual’s health picture. 

Albotherm’s vision is to revolutionise the cooling industry by providing a low carbon solution to temperature regulation. Initially focussing on the farming sector, Albotherm’s temperature-responsive materials will maximise food productivity in commercial greenhouses and contribute to a more sustainable and resilient food system. The technology also has wide applications in the building sector, where low carbon cooling systems are in high demand. Albotherm’s advanced materials use polymer chemistry to automatically switch from transparent to opaque above an engineerable trigger air-temperature, reflecting solar radiation without the need for active cooling systems like air conditioning. Albotherm’s initial focus is on commercial greenhouses, where they demonstrated 34% increase in crop yield compared to other approaches.

Esperto Medical was founded on the principles of making medical care more accessible through automation. Esperto aims to improve medical diagnostics so that clinicians and patients are no longer limited by a hospital environment. 

Esperto's first offering is a noninvasive, continuous blood pressure device to enable better vital sign monitoring at home, in the hospital, and maybe even in austere environments. Without an inflating cuff. It's based on first-principles physics: no guessing games, and no finnicky recalibration. 

Signapse provides a generative AI approach to translate from English to British Sign Language in Transport, Video Translation, and Websites

Innovation: Signapse are the first company to commercialise the use of computer vision and natural language processing techniques for text to sign language translations. Their generated videos are photorealistic, a game-changer for the Deaf Community who routinely reject graphical avatars that are employed by other startups.

Transdermal Diagnostics is developing a disposable needle-free patch capable of extracting and measuring biomarkers through natural pathways in the skin such as hair follicles. TD is first targeting glucose detection for T2 diabetics, a global health crisis affecting 536 million people.